Patent Issued for Engineered retrons and methods of use (USPTO 12054739).

Renagade Therapeutics Management Inc. has been issued a patent for engineered retrons and their use in genome editing. Retrons are DNA sequences that produce a unique satellite DNA called msDNA, which can be used as donor DNA templates for precise genome editing. The patent discusses the challenges of delivering donor DNA templates and proposes recombinant retrons with genetic modifications to improve their functionality. The patent also describes a gene editing system that utilizes delivery vehicles containing RNA cargo to modify genes in cells, including mRNA molecules encoding a programmable nuclease and a reverse transcriptase. This system can be used in various applications, such as gene therapy. The patent was filed by Brian Goodman and is assigned to Renagade Therapeutics Management Inc. [Extracted from the article]